drugset
drugset / Trial / NCT03446274

An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

NCT03446274 ↗

Phase 1 Unknown 6 enrolled Newron Pharmaceuticals SPA
NaSingle-groupOpen-labelBasic science

Summary

This is a single-center, open-label, non-randomized, single dose of 14C-NW-3509 capsule study in 6 healthy male subjects.

Timeline

Start
2018-04-02
Primary completion
2018-04-23
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Evenamide Small molecule — Oral

Indications

No indication recorded.